Clinical Trials on Fibrodysplasia Ossificans Progressiva (FOP) in United States

Total 16 results

Ipsen

Active, not recruiting

A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies. (PIVOINE)

Fibrodysplasia Ossificans Progressiva (FOP)

United States, France, Australia, Argentina, Italy, Canada, Sweden, United Kingdom, Brazil, Spain
Incyte Corporation

Recruiting

To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva (Progress)

Fibrodysplasia Ossificans Progressiva (FOP)

United States, France, Korea, Republic of, Spain, Italy, United Kingdom, Russian Federation, China, Australia, Brazil, Mexico, New Zealand, Argentina, Canada, Netherlands, Turkey, Chile, Germany, South Africa, Portugal
The International FOP Association

Recruiting

The Fibrodysplasia Ossificans Progressiva (FOP) Connection Registry

Fibrodysplasia Ossificans Progressiva (FOP)

United States
Regeneron Pharmaceuticals

Completed

A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)

Fibrodysplasia Ossificans Progressiva (FOP)

United States
Clementia Pharmaceuticals Inc.

Terminated

In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects

Fibrodysplasia Ossificans Progressiva

United States
Clementia Pharmaceuticals Inc.

Completed

An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva. (MOVE)

Fibrodysplasia Ossificans Progressiva

United States, Canada, France, Australia, Argentina, Brazil, Italy, Japan, Spain, Sweden, United Kingdom
Ipsen

Completed

An International Cross-sectional Survey to Evaluate the Burden of Fibrodysplasia Ossificans Progressiva (FOP) on Patients and Their Families.

Fibrodysplasia Ossificans Progressiva

United States
Novartis Pharmaceuticals

Completed

Urine Sample Collection From FOP Patients (FOP)

Fibrodysplasia Ossificans Progressiva

United States
Clementia Pharmaceuticals Inc.

Completed

Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects

Fibrodysplasia Ossificans Progressiva

United States
Regeneron Pharmaceuticals

Completed

A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva (LUMINA-1)

Fibrodysplasia Ossificans Progressiva

United States, Spain, Canada, France, Poland, Italy, Netherlands, United Kingdom
Clementia Pharmaceuticals Inc.
Ipsen

Recruiting

A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP). (FALKON)

Fibrodysplasia Ossificans Progressiva

United States, Korea, Republic of, Belgium, China, Sweden, France, Japan, Australia, Argentina, Brazil, Canada, Italy, Spain, United Kingdom, Mexico, Colombia, Netherlands, Germany, Portugal
Clementia Pharmaceuticals Inc.

Completed

An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects

Fibrodysplasia Ossificans Progressiva

United States, France, United Kingdom
Clementia Pharmaceuticals Inc.

Completed

A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)

Fibrodysplasia Ossificans Progressiva

United States, Argentina, Australia, France, United Kingdom, Italy
Clementia Pharmaceuticals Inc.

Completed

An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)

Fibrodysplasia Ossificans Progressiva

Australia, United States, Argentina, France, United Kingdom
Regeneron Pharmaceuticals

Recruiting

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP) (OPTIMA)

Fibrodysplasia Ossificans Progressiva

Japan, United States, Korea, Republic of, Spain, France, Australia, United Kingdom, China, Poland, Malaysia, Italy, Finland, Hong Kong, South Africa, Chile, Brazil, Netherlands, Colombia
Amsterdam UMC, location VUmc
AstraZeneca; Brigham and Women's Hospital; University of Oxford; Klinikum Garmisch-Patenkirchen and other collaborators

Recruiting

Saracatinib Trial TO Prevent FOP (STOPFOP)

Fibrodysplasia Ossificans Progressiva

Germany, Netherlands, United Kingdom

Clinical Trials on Fibrodysplasia Ossificans Progressiva (FOP) in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations